Home
NICE Guidance
Conditions and diseases
Musculoskeletal conditions
Osteoporosis
Explore
Register as a stakeholder
Show sections
4 new
and
1 updated
products since January 2017.
NICE Pathways - mapping our guidance
Osteoporosis
Technology appraisal guidance
Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women
(TA160)
October 2008
Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
(TA161)
October 2008
Denosumab for the prevention of osteoporotic fractures in postmenopausal women
(TA204)
October 2010
Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures
(TA279)
April 2013
NICE
Medtech innovation briefings
Bindex for investigating suspected osteoporosis
(MIB106)
May 2017
Quality standards
Osteoporosis
(QS149)
April 2017
NICE
Guidelines
Osteoporosis: assessing the risk of fragility fracture
(CG146)
August 2012
In development
Osteoporosis (prevention) - bisphosphonates (inc part rev TA160, TA161) [ID782]
(GID-TAG462)
TBC
Technology appraisal guidance
Osteoporotic fragility fractures (prevention) - abaloparatide, raloxifene , strontium ranelate, teriparatide and denosumab [ID901]
(GID-TA10072)
TBC
Technology appraisal guidance
Guidance
Resources
Savings and productivity
Local practice